A "systems medicine" approach to the study of non-alcoholic fatty liver disease

Salvatore Petta, Luca Valenti, Elisabetta Bugianesi, Giovanni Targher, Stefano Bellentani, Ferruccio Bonino, Silvia Fargion, Ester Vanni, Ele Ferrannini, Carmela Loguercio, Amedeo Lonardo, Fabio Marra, Marcello Mancini, Luca Miele, Valerio Nobili, Gianluca Svegliati Baroni, Federico Alessandro, Stefano Ballestri, Maurizia Rossana Brunetto, Barbara CocoAntonio Grieco, Loreta Kondili, Fabio Nascimbeni, Anna Prinster, Dante Romagnoli, Stefano Taddei, Stefano Vella

Research output: Contribution to journalArticle

Abstract

The prevalence of fatty liver (steatosis) in the general population is rapidly increasing worldwide. The progress of knowledge in the physiopathology of fatty liver is based on the systems biology approach to studying the complex interactions among different physiological systems. Similarly, translational and clinical research should address the complex interplay between these systems impacting on fatty liver. The clinical needs drive the applications of systems medicine to re-define clinical phenotypes, assessing the multiple nature of disease susceptibility and progression (e.g. the definition of risk, prognosis, diagnosis criteria, and new endpoints of clinical trials). Based on this premise and in light of recent findings, the complex mechanisms involved in the pathology of fatty liver and their impact on the short- and long-term clinical outcomes of cardiovascular, metabolic liver diseases associated with steatosis are presented in this review using a new "systems medicine" approach. A new data set is proposed for studying the impairments of different physiological systems that have an impact on fatty liver in different subsets of subjects and patients.

Original languageEnglish
Pages (from-to)333-342
Number of pages10
JournalDigestive and Liver Disease
Volume48
Issue number3
DOIs
Publication statusPublished - Mar 1 2016

Fingerprint

Fatty Liver
Systems Analysis
Translational Medical Research
Systems Biology
Disease Susceptibility
Metabolic Diseases
Disease Progression
Non-alcoholic Fatty Liver Disease
Liver Diseases
Clinical Trials
Pathology
Phenotype
Population

Keywords

  • Fatty liver
  • Medicine
  • NAFLD
  • NASH
  • Personalized
  • Systems medicine

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Petta, S., Valenti, L., Bugianesi, E., Targher, G., Bellentani, S., Bonino, F., ... Vella, S. (2016). A "systems medicine" approach to the study of non-alcoholic fatty liver disease. Digestive and Liver Disease, 48(3), 333-342. https://doi.org/10.1016/j.dld.2015.10.027

A "systems medicine" approach to the study of non-alcoholic fatty liver disease. / Petta, Salvatore; Valenti, Luca; Bugianesi, Elisabetta; Targher, Giovanni; Bellentani, Stefano; Bonino, Ferruccio; Fargion, Silvia; Vanni, Ester; Ferrannini, Ele; Loguercio, Carmela; Lonardo, Amedeo; Marra, Fabio; Mancini, Marcello; Miele, Luca; Nobili, Valerio; Baroni, Gianluca Svegliati; Alessandro, Federico; Ballestri, Stefano; Brunetto, Maurizia Rossana; Coco, Barbara; Grieco, Antonio; Kondili, Loreta; Nascimbeni, Fabio; Prinster, Anna; Romagnoli, Dante; Taddei, Stefano; Vella, Stefano.

In: Digestive and Liver Disease, Vol. 48, No. 3, 01.03.2016, p. 333-342.

Research output: Contribution to journalArticle

Petta, S, Valenti, L, Bugianesi, E, Targher, G, Bellentani, S, Bonino, F, Fargion, S, Vanni, E, Ferrannini, E, Loguercio, C, Lonardo, A, Marra, F, Mancini, M, Miele, L, Nobili, V, Baroni, GS, Alessandro, F, Ballestri, S, Brunetto, MR, Coco, B, Grieco, A, Kondili, L, Nascimbeni, F, Prinster, A, Romagnoli, D, Taddei, S & Vella, S 2016, 'A "systems medicine" approach to the study of non-alcoholic fatty liver disease', Digestive and Liver Disease, vol. 48, no. 3, pp. 333-342. https://doi.org/10.1016/j.dld.2015.10.027
Petta, Salvatore ; Valenti, Luca ; Bugianesi, Elisabetta ; Targher, Giovanni ; Bellentani, Stefano ; Bonino, Ferruccio ; Fargion, Silvia ; Vanni, Ester ; Ferrannini, Ele ; Loguercio, Carmela ; Lonardo, Amedeo ; Marra, Fabio ; Mancini, Marcello ; Miele, Luca ; Nobili, Valerio ; Baroni, Gianluca Svegliati ; Alessandro, Federico ; Ballestri, Stefano ; Brunetto, Maurizia Rossana ; Coco, Barbara ; Grieco, Antonio ; Kondili, Loreta ; Nascimbeni, Fabio ; Prinster, Anna ; Romagnoli, Dante ; Taddei, Stefano ; Vella, Stefano. / A "systems medicine" approach to the study of non-alcoholic fatty liver disease. In: Digestive and Liver Disease. 2016 ; Vol. 48, No. 3. pp. 333-342.
@article{9001f4380eea49bbaa3096271b45d8c2,
title = "A {"}systems medicine{"} approach to the study of non-alcoholic fatty liver disease",
abstract = "The prevalence of fatty liver (steatosis) in the general population is rapidly increasing worldwide. The progress of knowledge in the physiopathology of fatty liver is based on the systems biology approach to studying the complex interactions among different physiological systems. Similarly, translational and clinical research should address the complex interplay between these systems impacting on fatty liver. The clinical needs drive the applications of systems medicine to re-define clinical phenotypes, assessing the multiple nature of disease susceptibility and progression (e.g. the definition of risk, prognosis, diagnosis criteria, and new endpoints of clinical trials). Based on this premise and in light of recent findings, the complex mechanisms involved in the pathology of fatty liver and their impact on the short- and long-term clinical outcomes of cardiovascular, metabolic liver diseases associated with steatosis are presented in this review using a new {"}systems medicine{"} approach. A new data set is proposed for studying the impairments of different physiological systems that have an impact on fatty liver in different subsets of subjects and patients.",
keywords = "Fatty liver, Medicine, NAFLD, NASH, Personalized, Systems medicine",
author = "Salvatore Petta and Luca Valenti and Elisabetta Bugianesi and Giovanni Targher and Stefano Bellentani and Ferruccio Bonino and Silvia Fargion and Ester Vanni and Ele Ferrannini and Carmela Loguercio and Amedeo Lonardo and Fabio Marra and Marcello Mancini and Luca Miele and Valerio Nobili and Baroni, {Gianluca Svegliati} and Federico Alessandro and Stefano Ballestri and Brunetto, {Maurizia Rossana} and Barbara Coco and Antonio Grieco and Loreta Kondili and Fabio Nascimbeni and Anna Prinster and Dante Romagnoli and Stefano Taddei and Stefano Vella",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.dld.2015.10.027",
language = "English",
volume = "48",
pages = "333--342",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier B.V.",
number = "3",

}

TY - JOUR

T1 - A "systems medicine" approach to the study of non-alcoholic fatty liver disease

AU - Petta, Salvatore

AU - Valenti, Luca

AU - Bugianesi, Elisabetta

AU - Targher, Giovanni

AU - Bellentani, Stefano

AU - Bonino, Ferruccio

AU - Fargion, Silvia

AU - Vanni, Ester

AU - Ferrannini, Ele

AU - Loguercio, Carmela

AU - Lonardo, Amedeo

AU - Marra, Fabio

AU - Mancini, Marcello

AU - Miele, Luca

AU - Nobili, Valerio

AU - Baroni, Gianluca Svegliati

AU - Alessandro, Federico

AU - Ballestri, Stefano

AU - Brunetto, Maurizia Rossana

AU - Coco, Barbara

AU - Grieco, Antonio

AU - Kondili, Loreta

AU - Nascimbeni, Fabio

AU - Prinster, Anna

AU - Romagnoli, Dante

AU - Taddei, Stefano

AU - Vella, Stefano

PY - 2016/3/1

Y1 - 2016/3/1

N2 - The prevalence of fatty liver (steatosis) in the general population is rapidly increasing worldwide. The progress of knowledge in the physiopathology of fatty liver is based on the systems biology approach to studying the complex interactions among different physiological systems. Similarly, translational and clinical research should address the complex interplay between these systems impacting on fatty liver. The clinical needs drive the applications of systems medicine to re-define clinical phenotypes, assessing the multiple nature of disease susceptibility and progression (e.g. the definition of risk, prognosis, diagnosis criteria, and new endpoints of clinical trials). Based on this premise and in light of recent findings, the complex mechanisms involved in the pathology of fatty liver and their impact on the short- and long-term clinical outcomes of cardiovascular, metabolic liver diseases associated with steatosis are presented in this review using a new "systems medicine" approach. A new data set is proposed for studying the impairments of different physiological systems that have an impact on fatty liver in different subsets of subjects and patients.

AB - The prevalence of fatty liver (steatosis) in the general population is rapidly increasing worldwide. The progress of knowledge in the physiopathology of fatty liver is based on the systems biology approach to studying the complex interactions among different physiological systems. Similarly, translational and clinical research should address the complex interplay between these systems impacting on fatty liver. The clinical needs drive the applications of systems medicine to re-define clinical phenotypes, assessing the multiple nature of disease susceptibility and progression (e.g. the definition of risk, prognosis, diagnosis criteria, and new endpoints of clinical trials). Based on this premise and in light of recent findings, the complex mechanisms involved in the pathology of fatty liver and their impact on the short- and long-term clinical outcomes of cardiovascular, metabolic liver diseases associated with steatosis are presented in this review using a new "systems medicine" approach. A new data set is proposed for studying the impairments of different physiological systems that have an impact on fatty liver in different subsets of subjects and patients.

KW - Fatty liver

KW - Medicine

KW - NAFLD

KW - NASH

KW - Personalized

KW - Systems medicine

UR - http://www.scopus.com/inward/record.url?scp=84960463900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960463900&partnerID=8YFLogxK

U2 - 10.1016/j.dld.2015.10.027

DO - 10.1016/j.dld.2015.10.027

M3 - Article

AN - SCOPUS:84960463900

VL - 48

SP - 333

EP - 342

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

IS - 3

ER -